Sign up today for Psoriasis Cure Now’s free Psoriasis Health Tips Newsletter, distributed quarterly by email.

In each issue, we will deliver to you:

  • the latest developments on psoriasis treatment options;
  • seasonal strategies for minimizing the challenges posed by psoriasis and psoriatic arthritis;
  • information on clinical trials that are recruiting psoriasis patients across the United States;
  • easy to read summaries of the most important scientific papers concerning psoriatic disease;
  • and answers to reader questions.

You don’t want to miss any of the important news that could help you manage – and ultimately defeat – your psoriasis or psoriatic arthritis. Of course, if you ever decide you’re no longer interested in receiving it, just click the unsubscribe link at the bottom of every issue.

The nonprofit Psoriasis Cure Now educates psoriasis patients and the general public about psoriasis, and works for increased research on psoriatic disease and to ensure that patients can access the cutting-edge psoriasis and psoriatic arthritis therapies that are transforming lives.

If you have ideas, questions, or concerns, let us know.

The Latest Psoriasis News

Reading this article about the placebo effect will make you feel better today

Here’s a very interesting item about the placebo effect. Yes, it is fun to hear about experiments in which people can be fooled into feeling better, or worse. But more importantly, this professor and psychologist discusses how a patient’s attitude, and a physician’s warmth and (apparent) competence, can impact our Continue Reading…

“Fail first” insurance mandates not just a problem for U.S. psoriasis patients

“Fail first” policies are one of the mandates imposed by some U.S. health insurers to reduce their costs. They require that people with psoriasis (and other serious diseases) try older and inferior – and often less safe – treatments before they can access the 21st century treatments that work best. Continue Reading…

Imagine knowing after 4 weeks, how a new psoriasis treatment would be working for you after 6 months…

Here’s an interesting, after-the-fact analysis from clinical trials of the biologic Ilumya (tildrakizumab-asmn), an “IL-23 inhibitor” marketed by Sun Pharma. The researchers looked at psoriasis severity scores used in clinical trials, known as PASI scores (Psoriasis Area and Severity Index), for each patient. Each patient’s score is determined before the Continue Reading…

Join the Battle